An observational study in Bilateral Pleural Effusion and Pleurodesis, sponsored by European Institute of Oncology. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by European Institute of Oncology · Observational
Among 14 studies in Lung Neoplasms by European Institute of Oncology — 9 open to participants now, 9 under way, none of them phase 3. Lung Neoplasms · European Institute of Oncology.
Among the 14 studies in Lung Neoplasms by European Institute of Oncology, this one is the 10th largest by enrollment of the 11 observational ones, is the only one that started in 1998, is one of 3 of another kind, and was the 12th registered.
5,422 studies on the registry are indexed under Lung Neoplasms; 1,346 are open to participants now.
This study's enrollment of 31 is below the median of 200 across 1,434 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →9 of the 14 studies in Lung Neoplasms by European Institute of Oncology are open now, in 1 country. Each count lists the studies.
Of the 996 Lung Neoplasms studies recruiting now, 683 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →14 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 1 started in 1998.
Median enrollment 320 across the 3 interventional studies, 200 across the 11 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
European Institute of Oncology is the lead sponsor of 185 studies on the registry; 118 are open to participants now.
2 of the studies in Lung Neoplasms by European Institute of Oncology that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07909343European Institute of OncologyPatient Needs and Preferences for NSCL Cancer Treatment Monitoring | 2027-02-01 |
| NCT07325864European Institute of OncologyMolecular Phenotyping of Primitive Lung Cancer and Metastatic Site | 2027-06-30 |
Among the 14 studies in Lung Neoplasms by European Institute of Oncology, from their registry updates:
Investigate feasibility of synchronous bilateral talc pleurodesis for malignant bilateral pleural effusions
patient diagnosed with malignant pleural bilateral effusion
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patient diagnosed of malignant bilateral pleural effusions that underwent a synchronous bilateral talc pleurodesis
postoperative mortality
Evaluation of postoperative complications occurred after talc pleurodesis.
Time frame: 35 years
postoperative morbidity
Evaluation of postoperative complications occurred after talc pleurodesis.
Time frame: 35 years
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
European Institute of Oncology →